According to some estimates, nearly 40% of all living things are parasites. In their book Parasites: the inside story, Scott Lyell Gardner, Judy Diamond, and Gabor Rácz have revealed this figure. In a fascinating style, the authors describe the world o...

Up is the curve: a genealogy of healthcare in the developing world, written by Kiran Raj Pandey is an insightful compilation on the forces and undercurrents that have historically shaped developing world health systems—preeminent among them is a panopl...

Currently, tecovirimat has been authorised for emergency use in the treatment of severe mpox (formerly known as monkeypox).1 However, to date, studies on the pharmacokinetics and pharmacodynamics of tecovirimat in the genital compartment are absent.

The SARS-CoV-2 omicron lineage (B.1.1.529) continues to proliferate and evolve, leading to subvariants adept at evading antibody responses.1 Bivalent mRNA vaccines expressing both the omicron BA.5 spike and the ancestral D614G spike were introduced in ...

Molina KC, Ginde AA. Real-world use of nirmatrelvir–ritonavir: who benefits? Lancet Infect Dis 2023; published online March 15. https://doi.org/10.1016/S1473-3099(23)00180-9—In this Comment, Adit A Ginde's affiliation should have been “Department of Em...

Rapid antigen test devices (also known as lateral flow devices; LFDs) have emerged as an important tool in the early detection of SARS-CoV-2.1 In The Lancet Infectious Diseases, David Eyre and colleagues describe the clinical performance of three diffe...

Almost 9 million health-care-associated infections have been estimated to occur each year in European hospitals and long-term care facilities, and these lead to an increase in morbidity, mortality, bed occupancy, and duration of hospital stay. The aim ...

LFDs remained able to detect most SARS-CoV-2 infections throughout vaccine roll-out and across different viral variants. LFDs can potentially detect most infections that transmit to others and reduce the risk of transmission. However, performance is lo...

Domínguez J, Boeree MJ, Cambau E, et al. Clinical implications of molecular drug resistance testing for Mycobacterium tuberculosis: a 2023 TBnet/RESIST-TB consensus statement. Lancet Infect Dis 2023; 23: e122–37—In this Review, in table 2, “rrs full ge...

Adjunctive rosuvastatin at 10 mg once per day was safe but did not produce substantive benefits on culture conversion in the overall study population. Future trials could explore the safety and efficacy of higher doses of adjunctive rosuvastatin.

Tuberculosis (TB) is a major cause of illness and death globally, the annual WHO Global TB Report stated that 1·6 million people died from TB in 2022. In South Africa, TB remains the leading cause of death. The focal points of this epidemic are institu...

Khethiwe (name changed to protect privacy) did not understand what had been happening to her since she started taking medication for tuberculosis 2 weeks ago. Instead of feeling better—as the doctor promised she would—her fever returned and breathing w...

COVID-19 showed the value of international platform trials to produce rapid and robust evidence on the best way to treat and manage patients.1 The COVID-19 pandemic also revealed an urgent need to further improve the clinical trials ecosystem (ie, all ...

The nirsevimab binding site was highly conserved between 1956 and 2021. Nirsevimab escape variants were rare and have not increased over time.

Respiratory syncytial virus (RSV) was discovered in 1956,1 isolated from an infant with a respiratory illness in 1957,2 found to cause severe respiratory disease in immunocompromised individuals in 1985,3 and found to cause disease in those older than ...

We commend the study by Niklas Bobrovitz and colleagues,1 which systematically reviewed the evidence for the protective effect conferred by hybrid immunity (combination of infection and immunisation) in context of the SARS-CoV-2 omicron (B.1.1.529) var...